CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Cancer Network
Original article

<![CDATA[Monitoring, Educating Patients on Tarlatamab of ICANS and CRS Risk]]>

tarlatamabNeutral
AI Analysis

Summary

Dr. Laura Alder from Duke discusses patient monitoring and education strategies for managing immune-related toxicities including ICANS and CRS in patients receiving tarlatamab for brain metastases.

Importance:2/10
Sentiment:
0.00
patient monitoringimmunotherapyadverse eventsICANSCRSpatient education
Related Companies

Read the original article

Published by Cancer Network on August 18, 2026 3:00 PM

Read Original